To identify hypoxia- and immune-related prognosis markers for BLCA, we analyzed the mutation frequency of the model genes via CNV, and the results showed that TFRC had the highest acquired mutation frequency (Fig. 9B). This evidence concerns the gene TFRC and bladder transitional cell carcinoma.